4 results
The objective of this trial is to compare standard treatment with radium-223-chloride (proven surivval benefit) with treatment with rhenium-188-HEDP, which is nowadays only used for pain palliation. This trial includes patients with metastatic…
To assess the local and systemic safety and tolerability of continued ABBV-951 treatment delivered as a CSCI for 24 hours daily.
The current proof-of-concept study has been designed to assess the efficacy and safety of the Peregrine Kit in the treatment of subjects with hypertension, when discontinued from their antihypertensive medications. This will be an *off medication*…
To assess the local and systemic safety and tolerability of ABBV-951 delivered as a CSCI for 24 hours daily for up to 52 weeks.